Fig. 3: Fc effector functions exhibited by serum antibodies.

Plasma samples from individual NHPs for each individual adjuvant formulation was assessed for A ADCC with gp120-coated target cells, B A magnitude-breadth curve showing the percent peak activity ADCC response and breadth (number of isolates targeted) of an individual sample assayed against three different gp120s for the GTL assay or C three different HIV-1 IMCs for the Luc assay using samples from week 26. The x-axis represents the threshold of ADCC responses as peak activity for the three proteins, or three IMCs tested, whereas the y-axis represents the percent of the three targets showing ADCC responses. The AUCs between two groups were compared using Wilcoxon test. In the GTL and LUC assays, the AUC for percent peak activity for ALFQ significantly differed from ALFA group (p = 0.0215, p = 0.0061), and from AH group (p = 0.0550) in the LUC assay. None of the other groups showed any significance (p > 0.4428), D ADCP, E ADNP, and F ADCD. Data were graphed as mean ± SEM. Statistical comparisons between the different adjuvant groups were performed using the Kruskal–Wallis test with Dunn’s multiple comparison test. *p < 0.04, **p < 0.002, and ***p < 0.0008. Spearman correlation between avidity score and G ADCP, H ADNP, and I ADCD for week 26 are shown.